HC Wainwright Has Pessimistic Outlook of SLNO Q1 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for Soleno Therapeutics in a research note issued on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.83) per share for the quarter, down from their prior estimate of ($0.71). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.34) EPS.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.41).

SLNO has been the subject of a number of other reports. Robert W. Baird restated an “outperform” rating and issued a $72.00 price objective on shares of Soleno Therapeutics in a report on Monday, December 2nd. Stifel Nicolaus started coverage on Soleno Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $74.00 price target for the company. Finally, Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 4th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Soleno Therapeutics currently has an average rating of “Buy” and a consensus target price of $71.20.

Soleno Therapeutics Price Performance

SLNO opened at $44.99 on Thursday. The firm has a market cap of $1.94 billion, a PE ratio of -13.55 and a beta of -1.46. The stock has a 50-day moving average price of $47.20 and a 200-day moving average price of $49.86. Soleno Therapeutics has a 1 year low of $36.61 and a 1 year high of $60.92.

Institutional Investors Weigh In On Soleno Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC lifted its stake in Soleno Therapeutics by 6,048,754.5% in the 3rd quarter. FMR LLC now owns 665,374 shares of the company’s stock worth $33,595,000 after purchasing an additional 665,363 shares in the last quarter. Barclays PLC lifted its position in shares of Soleno Therapeutics by 149.3% in the third quarter. Barclays PLC now owns 52,545 shares of the company’s stock worth $2,652,000 after buying an additional 31,467 shares in the last quarter. State Street Corp boosted its stake in Soleno Therapeutics by 14.2% during the third quarter. State Street Corp now owns 1,142,169 shares of the company’s stock valued at $57,668,000 after buying an additional 142,033 shares during the last quarter. Holocene Advisors LP grew its holdings in Soleno Therapeutics by 10.8% during the 3rd quarter. Holocene Advisors LP now owns 594,364 shares of the company’s stock valued at $30,009,000 after buying an additional 57,913 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Soleno Therapeutics by 10.5% in the 3rd quarter. Geode Capital Management LLC now owns 540,296 shares of the company’s stock worth $27,286,000 after acquiring an additional 51,189 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Insider Activity at Soleno Therapeutics

In other news, CEO Bhatnagar Anish sold 10,937 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total value of $496,649.17. Following the completion of the sale, the chief executive officer now directly owns 708,616 shares of the company’s stock, valued at $32,178,252.56. This represents a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $46.18, for a total transaction of $108,061.20. Following the transaction, the insider now owns 76,605 shares in the company, valued at approximately $3,537,618.90. This trade represents a 2.96 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,360 shares of company stock worth $790,119. 12.30% of the stock is owned by company insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.